Survival rate was 61.8% for men with the mutation versus 94.3% for those without it.
Prostate cancer (PCa) patients with a BRCA2 mutation are more likely to die from the malignancy than those without the mutation, researchers reported online in the British Journal of Cancer.
Mohammad R. Akbari, MD, of the Women’s College Research Institute in Toronto, and colleagues identified 4,187 men who underwent a PCa biopsy from 1998 to 2010 as a result of an elevated PSA level or abnormal digital rectal examination.
They screened the entire BRCA2 gene for mutations and followed the men for death from PCa until December 2012. The 12-year PCa-specific survival rate was 61.8% for men with a BRCA2 mutation compared with 94.3% for men without a mutation.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.